Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

CANCER:

Multiple Myeloma

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	pomalidomide + elotuzumab Sensitive: A1 - Approval pomalidomide + elotuzumab Sensitive : A1	pomalidomide + elotuzumab Sensitive: A1 - Approval pomalidomide + elotuzumab Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	carfilzomib Sensitive: A1 - Approval carfilzomib Sensitive : A1	carfilzomib Sensitive: A1 - Approval carfilzomib Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	bortezomib + panobinostat Sensitive: A1 - Approval bortezomib + panobinostat Sensitive : A1	bortezomib + panobinostat Sensitive: A1 - Approval bortezomib + panobinostat Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	bortezomib + pegylated liposomal doxorubicin Sensitive: A1 - Approval bortezomib + pegylated liposomal doxorubicin Sensitive : A1	bortezomib + pegylated liposomal doxorubicin Sensitive: A1 - Approval bortezomib + pegylated liposomal doxorubicin Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	Sensitive: A1 - Approval Sensitive : A1	Sensitive: A1 - Approval Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	ciltacabtagene autoleucel Sensitive: A1 - Approval ciltacabtagene autoleucel Sensitive : A1	ciltacabtagene autoleucel Sensitive: A1 - Approval ciltacabtagene autoleucel Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	pomalidomide Sensitive: A1 - Approval pomalidomide Sensitive : A1	pomalidomide Sensitive: A1 - Approval pomalidomide Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	thalidomide Sensitive: A1 - Approval thalidomide Sensitive : A1	thalidomide Sensitive: A1 - Approval thalidomide Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	isatuximab-irfc Sensitive: A1 - Approval isatuximab-irfc Sensitive : A1	isatuximab-irfc Sensitive: A1 - Approval isatuximab-irfc Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	prednisone + thalidomide + melphalan Sensitive: A1 - Approval prednisone + thalidomide + melphalan Sensitive : A1	prednisone + thalidomide + melphalan Sensitive: A1 - Approval prednisone + thalidomide + melphalan Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	lenalidomide + daratumumab and hyaluronidase-fihj Sensitive: A1 - Approval lenalidomide + daratumumab and hyaluronidase-fihj Sensitive : A1	lenalidomide + daratumumab and hyaluronidase-fihj Sensitive: A1 - Approval lenalidomide + daratumumab and hyaluronidase-fihj Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	lenalidomide + elotuzumab Sensitive: A1 - Approval lenalidomide + elotuzumab Sensitive : A1	lenalidomide + elotuzumab Sensitive: A1 - Approval lenalidomide + elotuzumab Sensitive : A1